Skip to main content
. Author manuscript; available in PMC: 2010 Feb 18.
Published in final edited form as: Cancer Lett. 2008 Nov 5;274(2):313–318. doi: 10.1016/j.canlet.2008.09.033

Fig. 3.

Fig. 3

EMMPRIN expression required for bevacizumab response in vivo. (A) bevacizumab was effective in treating HNSCC xenografts in EMMPRIN expressing FaDu tumors (P = 0.0013), but response was not seen in tumors with knockdown EMMPRIN expression (FaDu/siE, P = 0.7942). Analysis of xenograft samples by immunohistochemistry staining for CD31 (B) revealed that bevacizumab decreased microvascular density of tumors that expressed EMMPRIN (P = 0.005), but had no effect on the vascularity of FaDu/siE tumors (P = 0.48). Immunohistochemistry of CD31 expression by FaDu control tumors (C) and tumors treated with bevacizumab (D) compared to FaDu/siE control (E) and treated (F) tumors. Data are normalized as percentage of untreated controls. Arrows indicate vascularity.